Prediction of pathological complete response (pCR) among HER2-positive breast cancer patients receiving trastuzumab-based neoadjuvant therapy has also been conducted by integrated analysis of mRNA and DNA mutation in pretreatment tumors (15). Here, ERBB2 is linked to breast carcinoma.